Anti-SARS-CoV-2 nucleocapsid antibody positivity 3 years after COVID-19

This study aimed to comprehensively assess anti-nucleocapsid antibody positivity using diverse commercial and in-house immunoassays among individuals who contracted COVID-19 more than 3 years ago. We enrolled 44 participants with laboratory-confirmed COVID-19 between January and May 2020 from Seoul National University Hospital and its community treatment centers. The results showed anti-nucleocapsid antibody positivities ranged from 45.5% to 87.9% depending upon the immunoassay used. The study highlights the importance of considering the limited anti-nucleocapsid antibody positivity in participants with a distant COVID-19 history in seroepidemiological or vaccine research.PMID:38684427 | DOI:10.7883/yoken.JJID.2024.011
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research